Arca
Skip to content
Tools
Tools

-cept

A receptor fusion protein: part of a receptor joined to an antibody's Fc region, soaking up the signal the receptor would bind.

  • Drugs ending in -cept: 40
  • Approved somewhere: 9
  • With a US drug page: 6

What it means

Stem from WHO's stem book, 2024; description by Arca
Stem
-cept
Class
Fusion proteins built from a receptor or its ligand, often joined to an antibody Fc
Most common targets
TNF (4), TNFSF13B (2), VEGFA (2), PGF (2), CD86 (2), CD80 (2), TNFSF13 (1), GAS6 (1)

Drugs that carry it

Approved and clinical-stage drugs in ChEMBL whose names ending in -cept or one of its sub-stems, matched by spelling; those with a US drug page link to it.
Acts on
AtaciceptPhase 3TNFSF13B, TNFSF13Tumor necrosis factor ligand superfamily member 13B inhibitor
TilmanoceptApproved—Diagnostic agent
BatiraxceptPhase 3GAS6Growth arrest-specific protein 6 inhibitor
GoflikiceptPhase 3——
TelitaciceptPhase 3——
EvorpaceptPhase 2CD47Leukocyte surface antigen CD47 inhibitor
LesigerceptPhase 2——
MaplirpaceptPhase 2——
OntorpaceptPhase 2——
ReciferceptPhase 2——
TimdarpaceptPhase 2——
ValzifloceptPhase 2——
AcazicolceptPhase 1——
DavoceticeptPhase 1——
InbakiceptPhase 1——
IpafriceptPhase 1FZD8Frizzled-8 antagonist
PovetaciceptPhase 1——
Briobacept—TNFSF13BTumor necrosis factor ligand superfamily member 13B inhibitor
AfliberceptApprovedVEGFA, PGFVascular endothelial growth factor A inhibitor
ConberceptPhase 3VEGFA, VEGFB, PGF, VEGFCVascular endothelial growth factor A inhibitor
SoziniberceptPhase 3——
Mirococept—CR1Complement receptor type 1 inhibitor
AlefaceptApprovedCD2T-cell surface antigen CD2 inhibitor
RilonaceptApprovedIL1BInterleukin-1 beta inhibitor
EtanerceptApprovedTNFTNF-alpha inhibitor
AsunerceptPhase 3FASLGTumor necrosis factor ligand superfamily member 6 binding agent
OnerceptPhase 3TNFTNF-alpha inhibitor
TanfanerceptPhase 3——
BaminerceptPhase 2LTA, LTB, TNFSF14Heterotrimeric lymphotoxin LTa1b2 inhibitor
PegsunerceptPhase 2TNFTNF-alpha inhibitor
Lenercept—TNFTNF-alpha inhibitor
Opinercept———
AbataceptApprovedCD86, CD80T-lymphocyte activation antigen CD86 inhibitor
BelataceptApprovedCD86, CD80T-lymphocyte activation antigen CD86 inhibitor
LuspaterceptApprovedTransforming growth factor betaTransforming growth factor beta inhibitor
SotaterceptApprovedINHBAInhibin beta A chain inhibitor
DalanterceptPhase 3GDF2, BMP10Growth/differentiation factor 2 inhibitor
RamaterceptPhase 2MSTNGrowth/differentiation factor 8 inhibitor
ElriterceptPhase 1——
Alvircept sudotoxPhase 1——

Stem from WHO, The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances (2024); description written by Arca. Drugs, stages, targets and mechanisms from ChEMBL (CC BY-SA 3.0). WHO

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.